NCT06534762 Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study
| NCT ID | NCT06534762 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Zhejiang Provincial People's Hospital |
| Condition | NSCLC |
| Study Type | INTERVENTIONAL |
| Enrollment | 260 participants |
| Start Date | 2024-07-15 |
| Primary Completion | 2026-07-01 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
This study is an exploratory study, and all the drugs involved are listed drugs. The dosage of mirabetron is selected according to the basis of previous research. The clinical recommend dose of this product is 50mg/day, and the dose used in this study is 100mg/day, which is larger than the clinical commonly used dose. The main adverse reactions of this product are urinary tract infection and rapid heartbeat. In the clinical study, we will focus on the urine routine and heart-related adverse events of the subjects, and deal with the adverse events in time. Subjects were given mirabeeron 100mg/day orally once a day in the morning until disease progression. When there are related or possible related side effects of the study drug mirabeeron, and according to NCI-CTCAE V 5.0, when subjects have more than or equal to grade 3 related toxicity, the administration should be delayed until grade 2 or lower to baseline, and the dose will be reduced by 50%, and subsequent dose increase is not allowed. If the pre-dose criteria are not met within 28 days, the drug will be permanently discontinued.
Eligibility Criteria
Inclusion Criteria: * Patients voluntarily participate in the study, sign informed consent, and have good compliance; * 18-65 years old (including 18 and 65 years old); * solid tumors confirmed by histology and/or cytology, and advanced metastatic tumors that are not feasible for surgical resection; * Has not received previous systemic antitumor drug therapy for metastatic/recurrent solid tumors; * For subjects who have previously received neoadjuvant/adjuvant therapy, it takes more than 6 months from the last treatment to relapse or progression; * Recovery of previous treatment-related AEs to National Cancer Institute Terminology Criteria for Common Adverse Events (NCI-CTCAE)≤ Grade 1 (excluding alopecia); * According to RECIST 1.1 standard, there is at least one measurable lesion assessed by the research center, and the measurable lesion should be a lesion that has not received local treatment such as radiotherapy (the lesion located in the region of previous radiotherapy can also be